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Weight lossHeart disease and related sequelae are a leading cause of death and healthcare expenditure throughout the
world. Althoughmany patients opt for surgical interventions, lifestyle modiﬁcation programs focusing on nutri-
tion and exercise have shown substantial health beneﬁts and are becoming increasing popular. We conducted a
year-long lifestylemodiﬁcation program tomediate cardiovascular risk through traditional risk factors and to in-
vestigate how molecular changes, if present, may contribute to long-term risk reduction. Here we describe the
lifestyle intervention, including clinical and molecular data collected, and provide details of the experimental
methods and quality control parameters for the gene expression data generated from participants and non-
intervention controls. Our ﬁndings suggest successful and sustained modulation of gene expression through
healthy lifestyle changesmay have beneﬁcial effects on vascular health that cannot be discerned from traditional
risk factor proﬁles. The data are deposited in the Gene Expression Omnibus, series GSE46097 and GSE66175.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).SpeciﬁcationsOrganism/cell
line/tissueHomo sapiens/whole bloodSex Male and female
Sequencer or
array typeAffymetrix GeneChip HG-U133A 2.0 arraysData format Raw data: CEL/TAR ﬁles, Normalized data: SOFT, MINiML, TXT
Experimental
factorsClinical: Standard demographic and clinical information,
physiological and biochemical assessment; Molecular: RNA
isolated from PAXgene™ tubes, globin reduction treatment of
RNA, standard Affymetrix expression analysis, transcript
validation by qRT-PCRExperimental
featuresIntensive lifestylemodiﬁcation to stabilize or reverse progression
of heart disease over 1 year; participants and retrospectively
matched controls with CAD or 2+ risk factors; group compari-
sons; risk factor correlations with gene expression; functional
enrichment and pathways analysis; medication inﬂuenceConsent All patients provided a written informed consent before
participation. The study protocol (Pro00009375) was
approved by the Chesapeake Institutional Review Board
(https://www.chesapeakeirb.com/).Sample source
locationWindber, Pennsylvania, USA, 620 Seventh Street, Windber,
worth).
. This is an open access article underDirect link to deposited data
The study is registered as NCT01805492 at ClinicalTrials.gov.
Expression data were deposited in the Gene Expression Omnibus
(GEO) under series accession numbers GSE46097 and GSE66175
and are available here: http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE46097 and http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE66175.
Experimental design, materials and methods
Objectives
Themain objectives of this projectwere to 1) characterize longitudi-
nal changes in gene expression in peripheral blood during an intensive
cardiovascular lifestyle intervention, and 2) identify associations be-
tween gene expression proﬁles and changes in quantitative heart
disease risk factors during the intervention. Our goal was to provide a
global view of molecular changes associated with drastic lifestyle
modiﬁcation designed to stabilize or reverse heart disease and ascertain
molecular pathways that are important in the development of coronary
atherosclerosis.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Inclusion criteria for participation included: 1) adult 21+ years of
age, 2)mentally competent to provide informed consent and accurately
report adherence, 3) physician diagnosis of coronary artery disease
(CAD), which included stable angina, angioplasty, N50% luminal
narrowing on coronary angiogram, acute myocardial infarction, bypass
surgery, or stent placement, or 2+ CAD risk factors such as obesity
(BMI N30), hypertension (systolic pressure N140 mm Hg or diastolic
pressure N90 mm Hg), high total cholesterol (N200 mg/dL), diabetes,
or family history of heart disease in parents or siblings, 4) approval
from personal physician, 5) desire to pursue intensive lifestyle modiﬁ-
cation as an alternative to, or in conjunction with, standard therapy
and motivation to follow the program guidelines for one year, and
6) successful abstinence from smoking for at least three months prior
to and during enrollment.
Exclusion criteria were: 1) b21 years of age, 2) presence of unstable
coronary syndromes, refractory congestive heart failure, uncontrolled
arrhythmia, or high-grade uncorrected cardiac conduction abnormali-
ties, 3) signiﬁcant left main stenosis (N50%) and ejection fraction
b35% in patients who did not have revascularization or were not candi-
dates for revascularization, 4) hypotensive response to exercise,
5) known history of autoimmune disease or systemic/chronic disease
requiring chemotherapy or long term treatment, 6) history of substance
abuse (including alcohol) without self-certiﬁcation of abstinence for at
least three months, and 7) physical disabilities or medical conditions
that would preclude program adherence.
Non-intervention controlswere recruited prospectively andmatched
to program participants based on age (within ±5 years), gender,
and disease status (presence of CAD or diabetes mellitus) [1]. Control
subjects received only standard care from their primary care physician,
did not receive any advice, counseling, or information regarding healthy
lifestyle behaviors, and did not participate in any component of the
lifestyle intervention.Fig. 1. Intensity graph showing the RMA normalized log2 intensity for each array. The
median intensity curve is highlighted in green.Intervention
A prospective nonrandomized trial based on the Multicenter Life-
style Demonstration Project was designed to stabilize or reverse pro-
gression of heart disease through comprehensive changes in lifestyle
[2]. Participants were recruited by referral from physicians and through
advertisements in the media. The lifestyle intervention consisted of a
low-fat vegetarian diet (b10% of calories from fat), 180 min/week of
moderate aerobic exercise, 1 h of stress management each day, and
weekly group support sessions. The year-long program was divided
into 2 stages, consisting of an intensive 3-month intervention during
which participants were taught to adopt and strictly adhere to the
program guidelines followed by a 9-month primarily self-directed
maintenance phase.
Clinical information was collected by review of medical records,
standard questionnaires, and physical examinations at the baseline,
3-month, and 1-year time points. Demographic and lifestyle factors
included the following: age, gender, ethnicity, family history of disease,
medication use, various psychometric parameters, and daily caloric
intake. Clinical information encompassed: height and weight, systolic
and diastolic blood pressure, general endurance, standard lipid panel,
lipoprotein proﬁles, and plasma biomarkers including C-reactive
protein, ultra-sensitive insulin, and leptin.
This research was conducted in accordance with the Code of Ethics
of theWorldMedical Association. Participants and controls volunteered
to participate in the research study and provided a written informed
consent. All research activities were governed by the United States
ArmyMedical Research andMateriel Command (MRMC)/Telemedicine
and Advanced Technology Research Center (TATRC) and the Henry M.
Jackson Foundation for the Advancement of Military Medicine. Ourdata reporting followed recommendations of the Transparent Reporting
of Evaluations with Nonrandomized Designs (TREND) group [3].
Blood collection, RNA isolation, and microarray analysis
Peripheral blood was collected from participants and controls at
each time point using the PreAnalytiX PAXgene™ Blood RNA System
(Qiagen, Valencia, CA). Blood was placed at room temperature for
4–24 h and frozen at−80 °C. PAXgene™ tubes were thawed overnight
at room temperature and RNA isolation was performed using the
PAXgene™ blood RNA Kit. Globin mRNA transcripts were depleted
from a portion of the total RNA using the GLOBINclear™-Human Kit
(Life Technologies, Carlsbad, CA). RNA quality was assessed with a
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA), and quantity
was measured with the Nanodrop ND-1000 spectrophotometer (Ther-
mo Scientiﬁc, Waltham, MA). One microgram of globin-depleted RNA
was then ampliﬁed using theMessageAmp™ II aRNA Ampliﬁcation Sys-
tem (Life Technologies). Resulting double-stranded cDNA was puriﬁed,
ampliﬁed, and labeled with biotin-11-UTP. Labeled aRNA (15 μg) was
subsequently fragmented and hybridized to GeneChip® Human
Genome U133A 2.0 arrays (Affymetrix, Santa Clara, CA) and scanned
on a GeneChip® Scanner 3000 using standard Affymetrix protocols.
All 3 time points for each participant/control were processed together
to minimize technical artifact. Further details of RNA isolation and
gene expression analysis are available in the Data Supplement of Ells-
worth et al. [4].
Quality control analysis
All CEL ﬁles (n = 480) were subjected to pre-processing using the
RobustMultichip Algorithm (RMA). Probe set intensities were obtained
by RMA background correction, quantile normalization, median polish
summarization, and log2 transformation. To assess data integrity, evalu-
ate assay performance, and ensure suitability for analysis, the processed
intensity data was subjected to standard GeneChip® quality control pa-
rameters: background intensity, raw noise (Q) values, percent present
calls, scaling factors, and GAPDH 3′/5′ ratio, and Actin 3′/5′ ratio. In
addition, the following QC assessments were conducted: array image
analysis to identify artifacts on the array surface, distribution analysis
to assess the spread of the data relative to the full probe set, and
principal component analysis to summarize overall variance.
Arrays included in the ﬁnal dataset passed the recommended
GeneChip® quality control assessments. The RMA normalized log2
intensity plot showed consistency of individual arrays relative to the
entire dataset (Fig. 1). Principal Component Analysis identiﬁed limited
variability attributable to laboratory procedures across all arrays
(Fig. 2). Comparable percent present values (median = 59.2%, range
48.1–64.8%), assessed using the mean absolute deviation, were ob-
served for all samples (Fig. 3).
Fig. 2. Three-dimensional scatter plot representing a Principal Component Analysis of all
expression arrays colored by laboratory technician.
52 H.L. Blackburn et al. / Genomics Data 4 (2015) 50–53Duplicate blood samples were collected from 7 randomly-selected
participants at each examination and applied to U133A 2.0 arrays
as outlined above to evaluate consistency of gene expression among
duplicate assays. The average Pearson correlation for the pair-wise
comparisons of RMA normalized intensities was 0.992 ± 0.006 (range
0.969–0.996) indicating high repeatability of the microarray data.
Paired t-tests identiﬁed 9 genes that were differentially expressed be-
tween duplicate samples based on a false discovery rate (FDR) adjusted
p-value b 0.05 and thus were excluded from further analysis: CKLF-like
MARVEL transmembrane domain containing 6 (CMTM6); dehydroge-
nase/reductase (SDR family) member 9 (DHRS9); guanine nucleotide
binding protein (G protein), α11 (GNA11); kelch-like 18 (KLHL18);
kinesin family member 1A (KIF1A); mitogen-activated protein kinase
1 interacting protein 1-like (MAPK1IP1L); nuclear receptor subfamily
3, group C, member 1 (glucocorticoid receptor) (NR3C1); transportin
1 (TNPO1); and vesicle-associated membrane protein 1 (synaptobrevin
1) (VAMP1).Fig. 3. Histogram (top panel) and scatter plot (bottom panel) showing the percentage of
probes on each array yielding detectable expression (percent present calls). The median
of the percent present calls is represented by the dashed green line and statistical limits
[±3.5 × STD (mean absolute deviation)] by the dashed red lines.Basic analyses
Our research summarizing changes in physiological [5] and psycho-
social risk factors [6], lipoprotein subclass proﬁles [7], and plasma
biomarkers of cardiometabolic risk [8] during the intensive lifestyle
intervention has been published previously. In all studies, lifestyle
participants experienced dramatic changes in dietary measures and
signiﬁcant improvement in a variety of cardiovascular risk factors
compared to controls.
For studies of gene expression,we ﬁrst selected a subset of 63 partic-
ipants and 63 matched controls to examine the impact of the lifestyle
program on individual gene expression proﬁles and regulatory
pathways important to cardiovascular health. Using ANOVA with FDR
correction for multiple testing, we identiﬁed 143 genes that were
differentially-expressed from baseline to 1 year in lifestyle participants
but observed little change in gene expression among controls. Lifestyle
modiﬁcation reduced the expression of proinﬂammatory genes associ-
atedwith neutrophil activation andmolecular pathways that are impor-
tant to vascular function [4].
Many genes with the largest fold-changes were signiﬁcantly corre-
lated with body mass index (BMI) throughout the lifestyle program;
therefore, we next examined relationships between weight loss and
changes in leukocyte gene expression in 89 lifestyle participants and
71 matched controls. Substantial weight loss (−15.2 ± 3.8%) during
the programwas associatedwith improvement in selected cardiovascu-
lar risk factors, signiﬁcant changes in gene expression, and alterations in
molecular pathways related to immune function and endothelial activa-
tion. Conversely, participants losing minimal weight (−3.1 ± 2.5%)
showed only minor changes in risk factors, markers of inﬂammation,
and gene expression compared to non-intervention controls [9].
Discussion
We describe detailed technical and analytical methods for a dataset
of 480 Affymetrix GeneChip® U133A 2.0 arrays from 89 participants in
an intensive year-long cardiovascular lifestyle intervention and 71
prospectively matched controls. To our knowledge, this is the largest
gene expression dataset on participants in a cardiovascular risk
reduction program. We believe this data will be of great value to future
investigations examining molecular changes that occur in patients
embracing healthy lifestyles in addition to the importance of lifestyle
in ameliorating cardiovascular risk.
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